Merck MRK
NYSE MRK
$148.79 +0.01 (+0.01%)
As of: Sep 28, 2026 · 3:59 PM EDT

Merck (MRK) Gains from Sales and Divestitures (2014)

Updated

Merck's Gains from Sales and Divestitures came in at $10.81 billion for Q4 2014.

Analysis

Merck (MRK) Gains from Sales and Divestitures (2014) Analysis & Trends

For FY2014, Merck's Gains from Sales and Divestitures was $11.21 billion.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 653.54 Bn 572.07 Bn 17.26 Bn
2 AbbVie 467.01 Bn 440.17 Bn 12.70 Bn
3 Merck 367.16 Bn 321.59 Bn 12.21 Bn
4 Novartis Ag 277.56 Bn 233.43 Bn 11.24 Bn
5 Astrazeneca 258.23 Bn 231.79 Bn 12.86 Bn
6 Amgen 224.14 Bn 179.54 Bn 7.24 Bn
7 Gilead Sciences 187.30 Bn 161.42 Bn 6.22 Bn
8 Pfizer 163.47 Bn 110.41 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.31 Bn 105.31 Bn 2.84 Bn
10 Bristol Myers Squibb 128.45 Bn 79.72 Bn 9.25 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 10.81 Bn
API Access

Merck Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=MRK&period=max&api_key=YOUR_API_KEY